Utah Medical Products stock: Revenue drop of 12.10 percent hits Utah Medical Products stock

Published on 10/24/2026 at 02:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Utah Medical Products stock, third-quarter sales were USD 8.62 million, down 12.10 percent. Net income rose 5.90 percent to USD 2.79 million.

Quarterly performance and capital return

Third-quarter sales reached USD 8.62 million for the period ended September 30, 2026.
Cash and investments stood at USD 85.2 million on September 30, 2026.
The tender offer expires on October 27, 2026, covering up to 650,000 shares.

UTMD, US9174881089, Illustration mit AI erstellt.

Utah Medical Products (ISIN US9174881089) reported third-quarter sales of USD 8.62 million for the period ended September 30, 2026, down 12.10 percent from the year-earlier quarter. According to Stockwatch, net income rose 5.90 percent to USD 2.79 million and diluted US GAAP earnings per share increased 6.80 percent to USD 0.88.

Three dated company developments

On September 30, 2026, the quarter ended with sales of USD 8.62 million and net income of USD 2.79 million. On October 5, 2026, Nasdaq reported that Utah Medical Products extended its offer to purchase up to 650,000 shares at USD 75.00 per share. On October 22, 2026, the company released its third-quarter and nine-month results, with nine-month sales of USD 25.87 million, down 12.20 percent year over year.

What does the margin change mean?

The operating picture was better than the sales line. Operating income rose 7.00 percent to USD 2.80 million in the third quarter, while the operating margin increased to 32.40 percent from 26.60 percent a year earlier, according to StockTitan. Lower litigation and intangible-asset amortization expenses helped offset weaker revenue.

The release also identified pressure from two former customers and lower Filshie Clip System sales. Femcare Ltd acquired Orion Medical Supplies at the end of August 2026 for USD 5.01 million, adding USD 0.62 million in third-quarter sales. Cash and investments were USD 85.2 million at September 30, 2026, while the company continued its share repurchases and dividends.

Next date is October 27

The next substantiated date is October 27, 2026, when the tender offer is scheduled to expire at 5:00 p.m. New York time. Its USD 75.00 offer price and 650,000-share limit give the capital-return plan a concrete deadline.

Market value and investor context

Utah Medical Products had a market capitalization of USD 235.6 million on October 23, 2026. Its Nasdaq-listed business develops and sells specialty medical devices for women's health, labor and delivery, neonatal care and related procedures, according to the company's Utah Medical Products investor-relations page.

The further course of trading is shown by the continuously updated real-time quote of Utah Medical Products stock.